{
    "nctId": "NCT00643513",
    "briefTitle": "Quality Of Life While Receiving Faslodex",
    "officialTitle": "Quality Of Life And Symptoms In Postmenopausal Women With Hormone Receptor Positive Disseminated Breast Cancer While Receiving Faslodex.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "To study QoL related response, symptom spectrum and severity in disseminated breast cancer patients receiving Faslodex hormonal therapy.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologic and/or cytological proven breast cancer.\n* Patients with metastases of breast cancer \u00b1 postmenopausal primary tumor \u226512 months.\n* Positive oestrogen receptors (ER+), positive progesterone receptors (PgR+) or unknown hormonal receptors (if duration between surgery and metastasis occurring is not less 2 years) which are indirect confirmation of hormone sensitive tumor.\n* ECOG performance status of \u2264 2\n* Patient willingness to take part in the programm\n* Life expectancy of more than 6 months.\n* Patient ability to complete a questionnaire.\n\nExclusion Criteria:\n\n* Contraindications for Faslodex therapy\n* Other anticancer therapy (chemotherapy, hormonal therapy with other drugs, radiotherapy), except for radiotherapy of sites which are not only measurable or evaluable manifestation of disease.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}